Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced its preliminary unaudited results for the financial year 2023.
– Medtronic deal accounted in 2024, to inject USD 200m cash
– FDA approval of GI Genius new enhanced operating system
– New GI drug development program announced
– Outlook for 2025